Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.53 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.53 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.53 |
| ▸ | EPOR | P19235 | 4/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CPB1 | P15086 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375887 | 1.00 | TPSAB1 (0.53) | TPSAB1TPSD1TPSG1EPORFOLH1 | |
| SCHEMBL4150947 | 1.00 | TPSAB1 (0.53) | TPSAB1TPSD1TPSG1EPORFOLH1 | |
| SCHEMBL28480221 | 0.97 | TPSAB1 (0.52) | TPSAB1TPSD1TPSG1EPORFOLH1 | |
| SCHEMBL5712142 | 0.97 | TPSAB1 (0.52) | TPSAB1TPSD1TPSG1EPORFOLH1 | |
| SCHEMBL1021829 | 0.97 | TPSAB1 (0.52) | TPSAB1TPSD1TPSG1EPORFOLH1 | |
| SCHEMBL7785339 | 0.93 | TPSAB1 (0.47) | TPSAB1TPSD1TPSG1EPORFOLH1 | |
| SCHEMBL5692891 | 0.91 | EPOR (0.55) | TPSAB1TPSD1TPSG1EPORFOLH1 | |
| SCHEMBL1491987 | 0.91 | EPOR (0.51) | TPSAB1TPSD1TPSG1EPORFOLH1 | |
| SCHEMBL22804052 | 0.91 | EPOR (0.51) | TPSAB1TPSD1TPSG1EPORFOLH1 | |
| SCHEMBL3776750 | 0.91 | EPOR (0.51) | TPSAB1TPSD1TPSG1EPORFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | claimed |
| EP-3432934-B1 | PRODRUGS OF CYTOTOXIC AGENTS WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma AG (DE) | 2022-02-23 | — | — | EP | disclosed |
| CN-112110834-A | Modified hydrophobic auxiliary material and preparation method and application thereof | 浙江智达药业有限公司 | 2020-12-22 | — | — | CN | disclosed |
| EP-3432934-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2019-01-30 | — | — | EP | disclosed |
| EP-3313525-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | Bayer Pharma Aktiengesellschaft (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-3313522-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | Bayer Pharma Aktiengesellschaft (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-3310440-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2018-04-25 | — | — | EP | disclosed |
| EP-3233127-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | Bayer Pharma Aktiengesellschaft (DE) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017162663-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-09-28 | — | — | WO | disclosed |
| WO-2016207103-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016207104-A1 | ANTIBODY DRUG CONJUGATES OF KINESIN SPINDEL PROTEIN (KSP) INHIBITORS WITH ANTI-B7H3-ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016207089-A1 | ANTIBODY DRUG CONJUGATES (ADCS) AND ANTIBODY PRODRUG CONJUGATES (APDCS) WITH ENZYMATICALLY CLEAVABLE GROUPS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016096610-A1 | ANTIBODY-DRUG CONJUGATES (ADCS) OF KSP INHIBITORS WITH AGLYCOSYLATED ANTI-TWEAKR ANTIBODIES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | WO | disclosed |
| EP-1625153-B1 | ACYLATED LYSOBACTIN-TYPE NONADEPSIPEPTIDES | AICURIS GMBH & CO KG (DE) | 2009-08-26 | — | — | EP | disclosed |
| US-5508432-A | TREATING GASTROINTESTINAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS | GLAXO WELLCOME INC. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5380872-A | Appetite suppresant, gall bladder disorders, CNS disorders | GLAXO INC. (US) | 1995-01-10 | — | — | US | disclosed |